{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion", "query": { "intervention": "Arm 2- Dose Expansion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-14T06:08:21.411Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03519984", "title": "EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Blasts 5 Percent or More of Bone Marrow Nucleated Cells", "Myelodysplastic/Myeloproliferative Neoplasm", "Philadelphia Chromosome Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Secondary Acute Myeloid Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" }, { "name": "Vincristine Liposomal", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-05-09", "completion_date": "2020-11-24", "has_results": false, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03519984" }, { "nct_id": "NCT04336098", "title": "Study of SRF617 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "SRF617", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Albumin-Bound Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2020-03-16", "completion_date": "2023-08-25", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 8, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04336098" }, { "nct_id": "NCT02107963", "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Osteosarcoma", "Neuroblastoma", "Melanoma" ], "interventions": [ { "name": "Anti-GD2-CAR engineered T cells", "type": "BIOLOGICAL" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 15, "start_date": "2014-02-28", "completion_date": "2017-01-31", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02107963" }, { "nct_id": "NCT04150562", "title": "Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear-Cell Renal Carcinoma" ], "interventions": [ { "name": "rhIL-15", "type": "DRUG" }, { "name": "Avelumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-05-26", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150562" }, { "nct_id": "NCT01445418", "title": "AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "AZ2281 + Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 103, "start_date": "2008-05-12", "completion_date": "2019-10-18", "has_results": false, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445418" }, { "nct_id": "NCT03177291", "title": "Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Non Small Cell Lung Cancer", "Advanced Cancer", "Metastatic Lung Cancer", "Squamous Cell Lung Cancer", "Non-Squamous Non-Small Cell Neoplasm of Lung" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2017-09-26", "completion_date": "2024-12-04", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03177291" }, { "nct_id": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT538", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Monoclonal antibody - Dose Escalation", "type": "COMBINATION_PRODUCT" }, { "name": "Monoclonal antibody - Dose Expansion", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-15", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05069935" }, { "nct_id": "NCT03075696", "title": "A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2017-02-21", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03075696" }, { "nct_id": "NCT03611556", "title": "MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Oleclumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 213, "start_date": "2018-06-21", "completion_date": "2022-07-22", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 18, "location_summary": "La Jolla, California • Aurora, Colorado • Fort Myers, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611556" }, { "nct_id": "NCT01433172", "title": "Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "Phase I - GM.CD40L.CCL21 Vaccinations", "type": "BIOLOGICAL" }, { "name": "Phase II - GM.CD40L cells Vaccinations", "type": "BIOLOGICAL" }, { "name": "Phase II - GM.CD40L.CCL21 Vaccinations", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2012-03-26", "completion_date": "2019-02-01", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-10-14T06:08:21.411Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433172" } ] }